Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 8, 2010, Pages 3758-3762

  Abdulrahman, Randa M ^a   Verloop, Herman ^a   Hoftijzer, Hendrieke ^a   Verburg, Erik ^b   Hovens, Guido C ^a   Corssmit, Eleonora P ^a   Reiners, Christoph ^b   Gelderblom, Hans ^a   Pereira, Alberto M ^a   Kapiteijn, Ellen ^a   Romijn, Johannes A ^a   Visser, Theo J ^c   Smit, Johannes W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5' TRIIODOTHYRONINE; IODOTHYRONINE; LEVOTHYROXINE; LIOTHYRONINE; SORAFENIB; THYROID HORMONE; THYROTROPIN; THYROXINE; THYROXINE DEIODINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEIODINATION; ENZYME ACTIVITY; FEMALE; FREE LIOTHYRONINE INDEX; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THYROID CARCINOMA; THYROID HORMONE BLOOD LEVEL; THYROID HORMONE METABOLISM; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 77955374095     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2507     Document Type: Article

References (20)

1. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664
2. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534
3. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83
4. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355
5. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019 (Pubitemid 350236338)
6. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454
7. Grossmann M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672
8. Faris JE, Moore AF, Daniels GH 2007 Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17:1147-1149
9. Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N, Wartofsky L 2008 Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 18:809-812
10. Kamba T, McDonald DM 2007 Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795
11. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576
12. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI 2008 Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265-268 (Pubitemid 351201706)
13. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP 2005 Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78:433-438
14. de Groot JW, Links TP, van der Graaf WT 2006 Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 17:1719-1720
15. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ, the Motesanib Thyroid Cancer Study Group 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42
16. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
17. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89
18. Eelkman Rooda SJ, Kaptein E, Visser TJ 1989 Serum triiodothyronine sulfate in man measured by radioimmunoassay. J Clin Endocrinol Metab 69:552-556
19. Hoftijzer H, Heemstra KA, Morreau H, Stokkel M, Corssmit EP, Gelderblom AJ, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931
20. Visser TJ, Docter R, Hennemann G 1977 Radioimmunoassay of reverse tri-iodothyronine. J Endocrinol 73:395-396